Common Variable Immunodeficiency clinical trials at UCSF

1 research study open to eligible people

Common variable immunodeficiency is a disorder that makes it hard for the body to fight infections. UCSF is studying a treatment called Abatacept for people with this condition who have lung disease. This trial is looking at how well this medicine works.

Showing trials for

  • Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

    open to eligible people ages 4 years and up

    There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD

    San Francisco, California and other locations

Our lead scientists for Common Variable Immunodeficiency research studies include .

Last updated: